Genetically modified tumor-targeted bacteria with reduced virulence
AssigneesVion Pharmaceuticals, Inc., Yale University
InventorsDavid Bermudes, Kenneth Brooks Low
Life of this patent
Estimating the term…
Abstract
The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purl gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
Claims13
A method of inhibiting the growth or reducing the volume of a solid tumor cancer, comprising administering an effective amount of a mutant Salmonella sp. to a patient having a solid tumor cancer, wherein said mutant Salmonella sp. comprises a disrupted msbB gene and is capable of targeting a solid tumor cancer when administered in vivo.
Dependencies are inferred from the claim text.